A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block CTLA-4, PD-1, or PD-L1 and induce the activation of the immune system against cancer. Despite the efficacy of ICIs, which has improved the oncotherapy for patients with a variety of malignancies, several immune-related adverse...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Revisão |
| שפה: | אנגלית |
| יצא לאור: |
2022
|
| גישה מקוונת: | https://doi.org/10.3389/fcell.2022.851032 https://www.frontiersin.org/articles/10.3389/fcell.2022.851032/pdf |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|